SAN JOSE, Calif., May 30, 2024 /PRNewswire/ -- Teikoku Pharma USA (TPU) announced today that the NMPA (National Medical Products Administration) has approved Lidoderm® ('lidocaine 5% patch as lidocaine cataplasms') for the treatment of Post Herpetic Neuralgia (PHN) in China. TPU entered into an exclusive licensing agreement with Link Healthcare Group (LHG) in 2018 to develop and distribute Lidoderm® in China..

加利福尼亚州圣何塞，2024年5月30日/PRNewswire/--Teikoku Pharma USA（TPU）今天宣布，NMPA（National Medical Products Administration）已批准利多卡因®（“5%利多卡因贴剂作为利多卡因巴布剂”）用于治疗中国的带状疱疹后神经痛（PHN）。2018年，TPU与Link Healthcare Group（LHG）签订了独家许可协议，在中国开发和分销Lidoderm®。。

Lidoderm® offers a topical and non-systemic approach for the treatment of neuropathic pain symptoms associated with PHN. Following a once daily 12 hours on/12 hours off application schedule, up to three patches can be used at one time.

Lidoderm®为治疗与PHN相关的神经性疼痛症状提供了一种局部和非全身的方法。按照每天一次12小时开/12小时关的应用程序时间表，一次最多可以使用三个补丁程序。

In the US, Lidoderm® is marketed by TPU Pharma (subsidiary of TPU) and its authorized generic lidocaine patch 5% is marketed by Endo USA, Inc. It is also marketed as Versatis® in Europe and Latin America by Grünenthal GmbH. Our lidocaine patch 5% has been marketed by our partners worldwide and over 3.7 billion patches have been delivered to patients since its launch.

在美国，Lidoderm®由TPU Pharma（TPU的子公司）销售，其授权的通用利多卡因贴剂5%由Endo USA，Inc.销售。Grünenthal GmbH在欧洲和拉丁美洲也以Versatis®的形式销售。我们的5%利多卡因贴剂已由我们的全球合作伙伴销售，自推出以来，已向患者提供了超过37亿个贴剂。

'Although this has been a long journey, we are happy to see Lidoderm® receive approval in China, an important market for our product that will also impact the lives of those suffering with Post Herpetic Neuralgia' said Paul Mori, CEO.

首席执行官保罗·莫里（PaulMori）说：“虽然这是一段漫长的旅程，但我们很高兴看到Lidoderm®在中国获得批准，这是我们产品的重要市场，也将影响带状疱疹后神经痛患者的生活。”。

About Teikoku Pharma USA

关于Teikoku Pharma USA

In collaboration with worldwide partners, TPU distributes its products to key markets globally. TPU excels not only in topical external preparations such as hydrogels, tapes and ointments, but also in systemic transdermal patches, solidifying its position as industry experts.

TPU与全球合作伙伴合作，将其产品分销到全球主要市场。TPU不仅在局部外用制剂（如水凝胶，胶带和软膏）方面表现出色，而且在全身透皮贴剂方面也表现出色，巩固了其行业专家的地位。

Lidoderm® is a hydrogel patch that contains 5% lidocaine. It offers a topical approach for the treatment of neuropathic pain symptoms associated with PHN.

Lidoderm®是一种含有5%利多卡因的水凝胶贴剂。它为治疗与PHN相关的神经性疼痛症状提供了一种局部方法。